STATISTICAL ASSESSMENT OF ENDOTHELINE-1 CONTENT AT DIFFERENT STAGES OF TYPE 1 DIABETES

To define the degree of affection of vessels an investigation of blood plasma of patients with type 1 diabetes (61 persons) and healthy donors living in Astrakhan region (24 persons) was carried out. The dependence of concentration of Endotheline-1 in blood plasma on the degree of affection of bloodstream of patients with diabetes was assessed

Modern approaches to pharmacotherapy of chronic gastritis

The definition of gastritis is based on the histological features of the gastric mucosa. This is not the erythema observed during gastroscopy, and there are no specific clinical manifestations or symptoms that determine it. The modern classification of gastritis is based on time (acute and chronic), histological features, anatomical distribution and the main pathological mechanisms. Acute gastritis will develop into chronic if left untreated. Helicobacter pylori (H. pylori) is the most common cause of gastritis worldwide. However, from 60 to 70% H. pylori-negative subjects with functional dyspepsia or non-erosive gastroesophageal reflux were also found to have gastritis. H. pylori-negative gastritis is considered when a person meets all four of these criteria: negative triple staining of biopsies of the gastric mucosa, no history of treatment of H. pylori. In these patients, the cause of gastritis may be associated with tobacco smoking, alcohol consumption and / or the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids. Other causes of gastritis include autoimmune gastritis associated with antibodies of serum anti-parietal and anti-internal factor; organisms other than H. pylori, such as Mycobacterium avium intracellulare, Herpes simplex and Cytomegalovirus; gastritis caused by acid reflux; Rare causes of gastritis include collagen gastritis, sarcoidosis, eosinophilic gastritis and lymphocytic gastritis. The clinical picture, laboratory studies, gastroscopy, as well as histological and microbiological examination of tissue biopsies are important for the diagnosis of gastritis and its causes. Treatment of gastritis caused by H. pylori leads to the rapid disappearance of polymorphic-nuclear infiltration and a decrease in chronic inflammatory infiltrate with gradual normalization of the mucous membrane. Other types of gastritis should be treated based on their etiology

Ventricular-arterial interaction in patients with is-chemic cardiomyopathy

This study examines the characteristics ventricular-arterial interaction and the efficiency of left ventricle in patients with ischemic cardiomyopathy. We examined 120 male patients (mean age 57,4±1,9 years) with ischemic cardiomyopathy. The comparison group consisted of 80 patients matched for gender and age (mean age of 58,1±1,7 years) with myocardial infarction in anamnesis and preserved systolic left ventricular function. Revealed that in patients with coronary heart disease is a disturbance of the interaction between left ventricle and arterial bed. In this case, patients with ischemic cardiomyopathy there is a distinct lack of reserve as left ventricular and arterial elastances. In this condition the trends of the external work of the left ventricle, the potential energy and the «pressure - volume» is increased and the mechanical efficiency of the left ventricle decreases

A CASE OF DILATED CARDIOMYOPATHY IN A PATIENT TREATED FROM ACUTE LEUKEMIA

A case of dilated cardiomyopathy in a patient treated from acute leukemia

Mutation status of refractory to imatinib patients with chronic myeloid leukemia

Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified mutations were missense mutations: Q252H, M244V, G250E, Y253F/H, E255K/V, T315I, M351T, F359V, F359C, F486S. Patients with BCR-ABL mutations have significantly lower 4-year event-free survival compared with CML patients without mutations (18 % vs. 53 %; р = 0.003). The results can be used as reference information in deciding on therapy in imatinib resistant CML patients with clinically relevant BCR-ABL mutations.</p

Mutation status of refractory to imatinib patients with chronic myeloid leukemia

Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified mutations were missense mutations: Q252H, M244V, G250E, Y253F/H, E255K/V, T315I, M351T, F359V, F359C, F486S. Patients with BCR-ABL mutations have significantly lower 4-year event-free survival compared with CML patients without mutations (18 % vs. 53 %; р = 0.003). The results can be used as reference information in deciding on therapy in imatinib resistant CML patients with clinically relevant BCR-ABL mutations